Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.5 USD | +3.01% | -1.39% | -37.70% |
25/04 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
25/04 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.70% | 789M | |
-1.46% | 103B | |
+7.87% | 101B | |
+4.40% | 23.07B | |
-12.22% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.63% | 16.94B | |
+6.85% | 14.07B | |
+38.63% | 12.35B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics : Names Chris Benecchi as Chief Commercial Officer